NasdaqGS:VRTXBiotechs
Vertex (VRTX) Stock May Sit Below Fair Value On Cash Flow
Vertex Pharmaceuticals stock has delivered a strong 5 year return of 145.1%. However, the current checks send a mixed message, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market based multiples look closer to fair.
Over the past 5 years, Vertex Pharmaceuticals has returned 145.1%, which puts current investors in the position of weighing further upside against an already successful run.
Expectations for continued cash flow generation from its...